Research Notes
Share to Facebook Share to Twitter Share to LinkedIn Pinterest Email

Lupus Discovery May Result in Promising Therapy

Lupus Discovery May Result in Promising Therapy

Einstein researchers and their colleagues have found a key cause of severe kidney complications affecting many patients with lupus, an inflammatory autoimmune disease, and are evaluating a promising treatment for preventing those complications.

Up to half of all lupus patients will develop lupus-related kidney inflammation, known as lupus nephritis. Left unchecked, lupus nephritis can cause irreversible kidney scarring that can result in organ failure and death.

Immune cells known as T cells contribute significantly to lupus kidney damage by infiltrating and inflaming kidney tissue. In a study published online in January 2022 in the Journal of Clinical Investigation, a team led by senior author Chaim Putterman, M.D., professor of medicine and of microbiology & immunology at Einstein, found that these T cells are activated by a protein called ALCAM, which is expressed by various tissues in the body.

In a phase 1 clinical trial, Dr. Putterman and colleagues are treating lupus patients with itolizumab, a novel monoclonal antibody that specifically prevents ALCAM from binding to and activating kidney-damaging T cells. Dr. Putterman is also the associate dean for research at the Azrieli Faculty of Medicine at Israel’s Bar-Ilan University.

Share to Facebook Share to Twitter Share to LinkedIn Share to Pinterest Email

More From Einstein

Class of 2022 Celebrates Match Day
Health Commissioner to Speak to Graduates
Student Researchers Win Marmur Award
Einstein Launches Mentor Training
Forbes Ranks Einstein as a Top Employer
Cancer Center Appoints New Leaders
Population Genetics and Cancer Inequities

Content

Highlights
Features
Campus News
Research Notes
Motivations: Donors & Alumni

Share

Share to Facebook Share to Twitter Share to LinkedIn Email

Past Issues

Download Magazine

Search

Subscribe